Skip to main content

Cardiovascular

Featured Article
According to researchers, recent study findings “do not support current recommendations to prefer chlorthalidone vs hydrochlorothiazide for hypertension treatment in first-time users.”
“By employing a student-driven curricular approach to screening for atrial fibrillation (AF), this study demonstrated that a high number of participants can be screened and educated about AF and its…

Insights

Mark Munger, PharmD, explains why pharmacists need to be vigilant on medication administration records for all patients, and intervene when necessary to avoid unnecessary drug misadventuring—especially in heart failure.
Mark Munger, PharmD, discusses why the search for improving outcomes in HFrEF using newer anti-coagulants continues.
Mark Munger, PharmD, discusses recent study findings, which show that ranolazine increases the adverse effect profile of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, raising concern for patient safety.
Kiersten Combs, vice president of US Cardiovascular & Metabolic Disease, and Jim McDermott, vice president of US Medical Affairs and Metabolism, both at AstraZeneca, highlight how the use of Farxiga and other SGLT2 inhibitors impact payers and…

Interactive Features

Among those who receive oral anticoagulation therapy, researchers were curious about the following question: “What are the longitudinal patterns of adherence to treatment with warfarin and direct oral anticoagulants among patients with atrial…
Most patients who received guideline-recommended medication had doses lower than those recommended, the researchers note.
What percentage of Medicare beneficiaries do not take their blood pressure medications as directed, according to the CDC?
A minimum of ___________ should elapse before patients who take patiromer for treatment of hyperkalemia ingest other oral medications.
Back to Top